Abstract: Objective The purpose of this study was to investigate the antiviral efficacy of pegylated interferon α-2a and albavir/granrivir combination in the treatment of patients with chronic hepatitis C (CHC). Methods 74 patients with CHC were encountered in our hospital between January 2018 and January 2022, and were randomly divided into control (n=37) and observation (n=37) group, receiving pegylated interferon α-2a and ribavirin therapy for 24 weeks, or pegylated interferon α-2a and albavir/granrivir combination therapy for 12 weeks. All patients were followed-up for 24 weeks after discontinuation of the antiviral treatment. Results The rapid virological response, early virological response, end of treatment virological response and sustained virological response in the observation were 70.3%, 89.2%, 89.2% and 94.6%, all significantly higher than 37.8%, 54.1%, 62.2% and 54.1%(P<0.05) in the control; at treatment week 4, week 12, week 24 and at follow-up 24 week, serum HCV RAN loads in the observation were (1.6±0.8)lg copies/L, (1.2±0.4)lg copies/L, (1.2±0.4)lg copies/L and (1.2±0.3)lg copies/L, all significantly lower than [(4.3±0.9) lg copies/L, (4.5±0.8)lg copies/L, (3.2±0.5)lg copies/L and (3.2±0.5)lg copies/L, respectively, P<0.05] in the control group; at the end of antiviral treatment, serum ALT and AST levels in the observation were (34.6±5.8)U/L and 36.4±6.9)U/L, both much lower than [(46.3±6.9)U/L and (49.1±7.5)U/L, respectively, P<0.05] in the control, while white blood cell counts, platelet counts and hemoglobin concentration in the two groups decreased obviously, without significant differences (P>0.05). Conclusion The combination of pegylated interferon α-2a and albavir/graniclovir therapy in the treatment of patients with CHC has a high virological response rate, which is beneficial to the recovery of liver function tests, showing a promising therapeutic outcomes.

Key words: Hepatitis C, Pegylated interferon α-2a, Albavir, Granrivir, Therapy